Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy
N Inui - Medical oncology, 2017 - Springer
Although antiemetic management in cancer therapy has improved, chemotherapy-induced
nausea and vomiting remain common and troubling adverse events. Chemotherapeutic …
nausea and vomiting remain common and troubling adverse events. Chemotherapeutic …
Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy
N Inui - Medical oncology (Northwood, London, England), 2017 - pubmed.ncbi.nlm.nih.gov
Although antiemetic management in cancer therapy has improved, chemotherapy-induced
nausea and vomiting remain common and troubling adverse events. Chemotherapeutic …
nausea and vomiting remain common and troubling adverse events. Chemotherapeutic …
Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy.
N Inui - Medical Oncology (Northwood, London, England), 2017 - europepmc.org
Although antiemetic management in cancer therapy has improved, chemotherapy-induced
nausea and vomiting remain common and troubling adverse events. Chemotherapeutic …
nausea and vomiting remain common and troubling adverse events. Chemotherapeutic …
Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy
N Inui - Medical Oncology, 2017 - infona.pl
Although antiemetic management in cancer therapy has improved, chemotherapy-induced
nausea and vomiting remain common and troubling adverse events. Chemotherapeutic …
nausea and vomiting remain common and troubling adverse events. Chemotherapeutic …
Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy
N Inui - Medical Oncology, 2017 - search.proquest.com
Although antiemetic management in cancer therapy has improved, chemotherapy-induced
nausea and vomiting remain common and troubling adverse events. Chemotherapeutic …
nausea and vomiting remain common and troubling adverse events. Chemotherapeutic …